#generic medical drugs manufacturer india

[livealthbiopharma]

Livealth Biopharma Pvt Ltd is the leading manufacturer and supplier of generic medical drugs and medicines across India.

[justinspoliticalcorner]

Lori Ann Larocco at CNBC:

Billions in trade came to a screeching halt at U.S. East Coast and Gulf Coast ports after members of the International Longshoremen’s Association (ILA) began walking off the job after 12:01 a.m. ET on October 1. The ILA is North America’s largest longshoremen’s union, with roughly 50,000 of its 85,000 members making good on the threat to strike at 14 major ports subject to a just-expired master contract with the United States Maritime Alliance (USMX), and picketing workers beginning to appear at ports. The union and port ownership group failed to reach agreement by midnight on a new contract in a protracted battle over wage increases and use of automation. In a last-ditch effort on Monday to avert a strike that will cause significant harm to the U.S. economy if it is lengthy — at least hundreds of millions of dollars a day at the largest ports like New York/New Jersey — the USMX offered a nearly 50% wage hike over six years, but that was rejected by the ILA, according to a source close to the negotiations. The port ownership group said it hoped the offer would lead to a resumption of collective bargaining.

The 14 ports where preparations for a strike have been underway are Boston, New York/New Jersey, Philadelphia, Wilmington, North Carolina, Baltimore, Norfolk, Charleston, Savannah, Jacksonville, Tampa, Miami, New Orleans, Mobile, and Houston. New York Governor Kathy Hochul said in a statement issued shortly after midnight that “the first large-scale eastern dockworker strike in 47 years began at ports from Maine to Texas, including at the Port Authority of New York and New Jersey. In preparation for this moment, New York has been working around the clock to ensure that our grocery stores and medical facilities have the essential products they need.” Rhetoric from ILA leadership has been aggressive in the weeks leading up to the strike, with ILA president Harold Daggett, who was a union member the last time it went out on strike in 1977, telling rank-and-file members — who unanimously voted to authorize a strike — in a recent video message, “We’ll crush them.” 

[...] The most significant issues would be faced by food and automobile industries, Kamins said, as they rely especially heavily on the ports that will be shut down. While a surge in inflation is highly unlikely even with a longer strike, even a modest reacceleration could create uncertainty and force the Federal Reserve to be more cautious about lowering interest rates, which would weigh on the overall outlook for job growth and investment. A one-week strike could cost the U.S. economy $3.78 billion, according to an analysis by The Conference Board, and cause supply chain slowdowns through mid-November. In all, the ports threatened with strikes handle $3 trillion annually in U.S. annual international trade.

Many industries are preparing for major repercussions. Noushin Shamsili, CEO and president of Nuco Logistics, which specializes in pharmaceutical imports and exports, said the strike comes at a critical time for inventory replenishment for the pharma sector. “Almost all of this industry is just on time,” said Shamsili. “Raw materials are being brought in to complete drug manufacturing. Medical supplies for clinics and hospitals are on these vessels. For a while importers did not bring in a lot of cargo because they were overflowing with supplies post-Covid. Now they have started reordering medical devices, gloves, syringes, and tubing.” Shamsili also said the East Coast ports are a gateway for generic medicine made in India. Approximately 48% of the active pharmaceutical ingredients used in the U.S. are being imported from India. Without these APIs, medications cannot be produced. APIs are also manufactured in Europe, which also use the East Coast ports as U.S. points of entry.

[...] The Biden administration finds itself in a delicate political moment, with the presidential election one month away and President Biden vowing he will not use existing labor law to force union workers back on the job, which is within his powers under the Taft-Hartley Act. The Taft-Hartley Act, passed in 1947, was a revision of U.S. law governing labor relations and union activity that granted a U.S. president the power to suspend a strike for an 80-day “cooling off period” in cases where “national health or safety” are at risk. 

Today begins the strike along East Coast and Gulf Coast ports after International Longshoremen’s Association (ILA) members walked off their jobs.

This strike, depending on how long it lasts, could have a major impact on the elections and the economy.

[madamlaydebug]

“If cannabis were discovered in the Amazon rainforest today, people would be clambering to make as much use as they could of all of the potential benefits of the plant. Unfortunately, it carries with it a long history of being a persecuted plant.” ~ Dr. Donald Abrams, Chief of Hematology Oncology at San Francisco General Hospital

Approximately 106,000 Americans die yearly from prescribed medications, according to the American Medical Association. Even more frightening, preventable medical errors account for a staggering 400,000 deaths in the U.S. each year — and is considered the 3rd leading cause of death. “It’s equivalent to 2,000 commercial jets taking off each year knowing that they don’t have enough fuel to complete their journeys,” notes Peter Edelstein M.D. “Would you allow your spouse to board one of those planes? Your friend? A stranger?”

Good question. Increasingly, people in the West are seeking out treatments that work harmoniously with the body, instead of against it — in other words, they’re walking away from the medical establishment and all its mishaps, mistakes and pharmaceutical drugs. A case in point is cannabis, especially in its raw form.

A Rich History

Marijuana is one of those plants that, to many, conjures visions of Drug Enforcement Administration (DEA) raids and hippies in a drugged-out daze. But it wasn’t always this way.

“The ancient Chinese knew of marijuana’s pain-relieving and mind-altering effects, yet it was not widely employed for its psychoactive properties; instead it was cultivated as hemp for the manufacture of rope and fabric. Likewise, the ancient Greeks and Romans used hemp to make rope and sails. In some other places, however, marijuana’s intoxicating properties became important. In India, for example, the plant was incorporated into religious rituals. During the Middle Ages, its use was common in Arab lands; in 15th-century Iraq it was used to treat epilepsy; in Egypt it was primarily consumed as an inebriant. After Napoleon’s occupation of Egypt, Europeans began using the drug as an intoxicant. During the slave trade, it was transported from Africa to Mexico, the Caribbean and South America. Marijuana gained a following in the U.S. only relatively recently. During the second half of the 19th century and the beginning of the 20th, cannabis was freely available without a prescription for a wide range of ailments, including migraine and ulcers,” Roger A. Nicoll and Bradley N. Alger remind us in Scientific American.

Even American Founding Father Thomas Jefferson declared: “Hemp is of first necessity to the wealth and protection of the country.”

So what happened?

In 1937, the United States Congress decided — against the recommendation of the American Medical Association — to pass the Marijuana Tax Act. The legislation essentially banned the use of marijuana by making it excessively expensive and difficult to secure. It has been downhill ever since. That is, until the last few years where legalization of marijuana has exploded in the U.S., for both recreational and medicinal uses. For our purposes here, we’re going to look at the health benefits of the plant — which are quite impressive.

An Essential Vegetable

“It [cannabis] has captured these molecules that help our bodies regulatory system be more effective. The bottom line is it’s a dietary essential that helps all 210 cell types function more effectively. I don’t even refer to it as medicine anymore, strictly as a dietary essential.”

~ Dr. William L. Courtney

It may be a stretch for some to recognize rawcannabis as the next in-demand superfood, but Dr. Courtney, a physician with extensive medical training who specializes in the dietary uses of cannabis, presents a provocative case.

When you heat or age cannabis, Dr. Courtney believes that you lose 99% of the benefit cannabis provides. In contrast, if you consume it raw, you’ll reap the full value of the plant. Plus, raw cannabis is non-psychoactive, so you won’t experience a high — an important point for those who would like to utilize the healing aspects of cannabis without feeling drugged or off-center. This means you can also consume a much higher amount of health-promoting compounds with raw cannabis juice compared to if it was smoked or extracted as an oil, according to Dr. Courtney.

Terpenes, essential oils found in cannabis which give the plant its unique aroma, are particularly compelling.A study published in the British Journal of Pharmacology states that terpenoids are “pharmacologically versatile: they are lipophilic, interact with cell membranes, neuronal and muscle ion channels, neurotransmitter receptors, G-protein coupled (odorant) receptors, second messenger systems and enzymes.”

The researchers explored the powerful effect terpenes exert in animal tests. Limonene was found to increase serotonin in the prefrontal cortex and dopamine in the hippocampus region of the brain — both of which help fend-offdepression and feelings of stress. Moreover, limonene induces apoptosis (cell death) of breast cancer cells and demonstrated exceptional radical scavenging properties. It’s also remarkably bioavailable, rapidly metabolized and is highly non-toxic and non-sensitizing.

Myrcene is anti-inflammatory and an effective sleep aid, while pinene acts as a bronchodilator and broad spectrum antibiotic — including the destruction of lethal MRSA bacteria. Pinene also curbs inflammation. Linalool is a sedative and anticonvulsant. Caryophyllene is antimalarial, anti-inflammatory and useful in treating duodenal ulcers. Nerolidol inhibits fungal growth and protozoal parasites. Phytol increases GABA expression, resulting in a calming effect. These are just a handful of the 200 varieties of terpenes found in cannabis.

How to Enjoy More Raw Cannabis in Your Life

For a daily dose, Dr. Courtney advises juicing fifteen cannabis leaves and two buds, which is then added to a small amount of fruit or vegetable juice that is consumed throughout the day. If you would like to learn more about juicing cannabis, this article offers tips and suggestions. Keep in mind that juicing improperly may create heat, which will cause THC to form. Jeffrey C. Raber, Ph.D. also recommends having the strain of marijuana you’re using tested at a reliable and accurate lab so you know exactly what you are getting.

Article sources:

www.psychologytoday.com

www.humboldtjustice.com

www.globalhealingcenter.com

www.cannabisinternational.org

www.ncbi.nlm.nih.gov

www.huffingtonpost.com

www.projectcbd.org

[theculturedmarxist]

I can't reblog it for some reason, but regarding a thread about how awful Mao is and how his policies killed a hundred billion people, I think this is significant.

---

DETROIT — Another country that once had an addiction problem—one that lasted for almost 200 years and involved an incredible 25 per cent of its population—is China.

Today China is virtually drug‐free— and the methods the Chinese used to eradicate their addiction problem might well offer methods we could use to achieve the same results.

China was forced into addiction by the Opium Wars. Contrary to popular belief, these wars—from 1839 to 1842 —did not originate because China wanted to export opium. They began when China resisted England's demand to import opium in exchange for Chi nese products—mostly tea, silk, and porcelain. China lost these wars, and among other indignities was forced to exchange its goods for opium. As a result it became a highly narcoticized country, a victim of ruthless Western economic and political policy. By 1850 an entire fifth of the revenue of the British Government of India — the source of opium — came from Chinese consumption of this drug.

Obviously to enlarge the market for opium, China was forced to create a huge number of addicts. And it did.

In October of 1949 the People's Re public of China was proclaimed. With in a year the Communist Government instituted a comprehensive program designed to eliminate this threat to the nation. All evidence indicates that by 1953 the problem of narcotic drug abuse was practically eliminated.

One important factor was the changed ideology of the young people —no new supply of addicts was forth coming. The changes in outlook in cluded a redefinition of the nation and its youth, of their worth and role. In rural areas this new definition was based on land distribution; collective farming; new educational, social, and vocational opportunities; and the elec tion of local councils. In the cities it took the form of nationalization of commerce and industry, full employ ment, worker control, and the end of foreign domination.

This total ideological transformation of the younger generation was accom panied by the reintegration of Chinese society through small street commit tees that offered cultural leadership.

Equally significant in the Chinese drive to eliminate narcotic addiction were its methods of plugging the source, China is 80 per cent rural, and an unknown but significant part of the land had been turned into poppy cul tivation. The first major economic and political mass campaign of the Gov ernment was land reform, and this aim was coordinated with elimination of poppy growth. Distribution of land from large landholders to landless peasants was accompanied by the need to convert the opium cash crops to badly needed food crops. Today China produces enough opium to meet its medical needs, but no more.

Smuggled opium was still a source of the drug, and China acted to stop this supply with a policy of “carrot and stick.” Leniency was recom mended for employes and workers of opium traffickers; but heavy penalties existed for those controlling the traf fic, manufacture, or growth of opium.

China's attitude toward the individ ual reformed addict was one of good willed congratulations, and represents another important reason why the nar cotic problem was overcome. The re habilitation of opium addicts began with their registration. Arrangements by city‐wide antiopium committees for addict rehabilitation included treat ment to break the habit at home, in clinics and in hospitals.

At every stage of personal rehabili tation the ideological motivation was stressed. Given China's attitudes, this ideology was strong on political, so cial, and economic information. But the important thing is that the anti drug campaign recognized that the de sire and will of the addict is ultimately the controlling factor of addiction. China's policy was not simply to de prive a person of drugs, but to replace the need for narcotics with a forceful, national commitment. Equally signifi cant, the former addict was fully ac cepted back into Chinese life without official stigma or prejudice.

Naturally, many questions have to be answered about the total success of the Chinese experience. Is there an addict population living in labor camps or prisons because of failure to re habilitate? Do the rehabilitated addicts all function as useful members of Chi nese society? To what extent would addiction be a problem in China if its internal and border controls were less stringent? Does traditional Chinese medicine offer useful ideas about ad diction treatment?

---

Wikipedia puts the census count in 1950 at 546,815,000, and a quarter of that is 136,703,750. So about that many people saved from opium addiction by the Communists.

I wonder if that's the reason the West wants to focus so much on the famine.

[latestmarketresearchnews]

Pharmaceutical Packaging Market 2030 Top Key Players, Trends, Share, Industry Size, Segmentation

The global pharmaceutical packaging market was valued at USD 139.37 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2030. This growth is largely driven by the rapid expansion of the pharmaceutical industry, which has been advancing due to scientific and technological innovations. The ongoing growth is expected to continue, especially in developing regions such as China, India, Saudi Arabia, and Brazil, where healthcare infrastructure and demand for medicines are expanding significantly.

In 2023, the United States represented the largest pharmaceutical market globally. Several factors contribute to this, including a well-established healthcare system, high per capita income, and substantial investments in research and drug development. The increasing focus on generic drugs and the improvement in healthcare services are expected to provide promising opportunities for the pharmaceutical packaging market. Notably, the 21st Century Cures Act (Cures Act), signed in 2016, is aimed at accelerating medical product development in the U.S., thus fostering innovation in the pharmaceutical industry. This legislation is anticipated to boost demand for pharmaceutical packaging by supporting the launch of new and innovative drug formulations.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Packaging Market

Europe’s pharmaceutical sector is one of its high-performing and technologically advanced industries, significantly contributing to the regional economy. The sector is evolving with an increased focus on developing biopharmaceutical drugs, which has grown over recent years. Many biotechnology-based drug therapies are sensitive to degradation and thus require specialized packaging, such as lyophilized or dry powder forms, to maintain stability. This demand for sophisticated packaging solutions is creating new growth opportunities for packaging manufacturers.

Pharmaceutical products are primarily available in forms such as tablets, capsules, liquids, and powders. They require various packaging solutions, including rigid bottles, stand-up pouches, flat pouches, sachets, and blister packs, each designed to meet specific needs. Packaging companies are now prioritizing features like dispensing aids, administration tools, eco-friendly materials, tamper-evident seals, and anti-counterfeiting measures to enhance product safety, accessibility, and sustainability.

End-use Segmentation Insights:

The pharma manufacturing segment was the largest end-use segment in 2023, accounting for a 49.9% market share, and is anticipated to see strong growth through to 2030. This trend is primarily due to the rising demand for medicines worldwide. According to the World Health Organization (WHO), the global population aged over 60 is expected to nearly double from 12% in 2015 to 22% by 2050, increasing the need for medicines and healthcare. The aging population requires more medical assistance, which is driving pharmaceutical production and, subsequently, the demand for pharmaceutical packaging.

To manage costs and increase efficiency, pharmaceutical companies are increasingly outsourcing packaging activities. By outsourcing, companies can avoid investing directly in packaging materials and equipment, instead working with specialized contractors who provide efficient packaging solutions. This shift is expected to fuel demand for contract manufacturing and pharmaceutical packaging equipment.

Retail pharmacies, especially in developing countries like India, China, and Brazil, are using branding on packaging materials such as polybags and paper pouches to differentiate their products. As retail penetration expands in these regions, the retail pharmacy segment is likely to see significant growth.

Institutional pharmacies, which operate within healthcare facilities like hospitals, nursing homes, and assisted living communities, are expected to grow as well. The increasing number of hospitals and healthcare facilities, along with rising healthcare expenditures, is likely to drive demand for pharmaceutical packaging in this segment. With a growing focus on healthcare accessibility and quality, the institutional pharmacy end-use sector is anticipated to contribute significantly to the overall growth of the pharmaceutical packaging market.

Order a free sample PDF of the Pharmaceutical Packaging Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

Pharmaceutical Packaging Market 2030 Driving Factors, Future Trends, Size & Key Vendors

The global pharmaceutical packaging market was valued at USD 139.37 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2030. This growth is largely driven by the rapid expansion of the pharmaceutical industry, which has been advancing due to scientific and technological innovations. The ongoing growth is expected to continue, especially in developing regions such as China, India, Saudi Arabia, and Brazil, where healthcare infrastructure and demand for medicines are expanding significantly.

In 2023, the United States represented the largest pharmaceutical market globally. Several factors contribute to this, including a well-established healthcare system, high per capita income, and substantial investments in research and drug development. The increasing focus on generic drugs and the improvement in healthcare services are expected to provide promising opportunities for the pharmaceutical packaging market. Notably, the 21st Century Cures Act (Cures Act), signed in 2016, is aimed at accelerating medical product development in the U.S., thus fostering innovation in the pharmaceutical industry. This legislation is anticipated to boost demand for pharmaceutical packaging by supporting the launch of new and innovative drug formulations.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Packaging Market

Europe’s pharmaceutical sector is one of its high-performing and technologically advanced industries, significantly contributing to the regional economy. The sector is evolving with an increased focus on developing biopharmaceutical drugs, which has grown over recent years. Many biotechnology-based drug therapies are sensitive to degradation and thus require specialized packaging, such as lyophilized or dry powder forms, to maintain stability. This demand for sophisticated packaging solutions is creating new growth opportunities for packaging manufacturers.

Pharmaceutical products are primarily available in forms such as tablets, capsules, liquids, and powders. They require various packaging solutions, including rigid bottles, stand-up pouches, flat pouches, sachets, and blister packs, each designed to meet specific needs. Packaging companies are now prioritizing features like dispensing aids, administration tools, eco-friendly materials, tamper-evident seals, and anti-counterfeiting measures to enhance product safety, accessibility, and sustainability.

End-use Segmentation Insights:

The pharma manufacturing segment was the largest end-use segment in 2023, accounting for a 49.9% market share, and is anticipated to see strong growth through to 2030. This trend is primarily due to the rising demand for medicines worldwide. According to the World Health Organization (WHO), the global population aged over 60 is expected to nearly double from 12% in 2015 to 22% by 2050, increasing the need for medicines and healthcare. The aging population requires more medical assistance, which is driving pharmaceutical production and, subsequently, the demand for pharmaceutical packaging.

To manage costs and increase efficiency, pharmaceutical companies are increasingly outsourcing packaging activities. By outsourcing, companies can avoid investing directly in packaging materials and equipment, instead working with specialized contractors who provide efficient packaging solutions. This shift is expected to fuel demand for contract manufacturing and pharmaceutical packaging equipment.

Retail pharmacies, especially in developing countries like India, China, and Brazil, are using branding on packaging materials such as polybags and paper pouches to differentiate their products. As retail penetration expands in these regions, the retail pharmacy segment is likely to see significant growth.

Institutional pharmacies, which operate within healthcare facilities like hospitals, nursing homes, and assisted living communities, are expected to grow as well. The increasing number of hospitals and healthcare facilities, along with rising healthcare expenditures, is likely to drive demand for pharmaceutical packaging in this segment. With a growing focus on healthcare accessibility and quality, the institutional pharmacy end-use sector is anticipated to contribute significantly to the overall growth of the pharmaceutical packaging market.

Order a free sample PDF of the Pharmaceutical Packaging Market Intelligence Study, published by Grand View Research.

[oasisbiobloom]

How to Conduct Market Research Before Starting Your PCD Franchise

Starting your own PCD franchise in the pharmaceutical industry is an exciting opportunity, but like any business venture, it requires thorough planning and research to ensure success. One of the most important steps in preparing for your PCD franchise is conducting comprehensive market research. A well-researched market approach will help you understand the demand for pharmaceutical products in your region, identify competition, and choose the best PCD company in India to partner with.

Here’s a step-by-step guide on how to conduct market research before launching your PCD franchise:

Step 1: Define Your Target Market

The first step in any market research is identifying your target market. In the case of a PCD franchise, your primary customers will likely be local healthcare providers, such as:

Doctors and specialists: Medical professionals who will prescribe the medicines.

Chemists and pharmacies: Retailers who will sell the medicines.

Hospitals and clinics: Medical institutions that need regular supplies of pharmaceuticals.

Understanding who your customers are will help you tailor your marketing efforts and ensure you stock the right products.

To get started:

Analyze local healthcare trends: Are there rising health concerns or specific diseases prevalent in your area? This will determine the types of medicines you need to focus on.

Check demographics: Look into the age, income levels, and healthcare needs of people in your area. Rural areas, for example, might have different healthcare needs than urban centers.

Step 2: Research the Demand for Pharmaceutical Products

Next, it’s crucial to assess the demand for pharmaceutical products in your region. Knowing which types of drugs are in high demand will help you align your franchise with the most profitable product categories.

Key product categories to research include:

Generic medicines: Affordable alternatives to branded drugs are in high demand in many markets.

Nutraceuticals and wellness products: With increasing health awareness, people are turning to supplements and wellness products.

Over-the-counter (OTC) medications: Non-prescription drugs like pain relievers, cold medicines, and vitamins.

You can find data about product demand by:

Talking to local chemists and doctors: Their feedback on what products are frequently sold and prescribed can give you insights into the market.

Reviewing sales reports and market surveys: Reports from pharmaceutical industry associations or trade groups can offer valuable data on current market trends and projections.

Step 3: Analyze Local Competition

Understanding the competitive landscape is a critical part of market research for your PCD franchise. You’ll need to identify both direct and indirect competitors who are already distributing similar products in your area.

Direct competitors: Other PCD franchisees and distributors offering similar pharmaceutical products.

Indirect competitors: These could include wholesalers, manufacturers, and even online pharmacies.

Look for:

Competitors' product range: Are they offering a broad range of pharmaceutical products, or are they focused on a niche market?

Pricing strategies: What price points are your competitors offering? You’ll need to determine if you can compete with similar prices or if you’ll need to differentiate by offering higher-quality products or better customer service.

Promotional efforts: How do competitors market themselves? Do they focus on doctors, hospitals, or direct-to-consumer sales?

To gain insights, you can:

Visit local pharmacies and clinics: Understand what products are being prescribed or sold.

Monitor online pharmacies and distributors: Check how competitors are positioning themselves in the digital space.

Step 4: Evaluate the Best PCD Companies in India

Once you have a good understanding of the demand and competition in your area, it's time to evaluate potential PCD companies to partner with. Choosing the best PCD company in India is a critical decision that will impact your franchise’s success.

Factors to consider:

Product quality: Partner with companies that adhere to high manufacturing standards such as GMP (Good Manufacturing Practices), ISO certifications, and WHO compliance. This ensures you’re distributing quality products that your customers trust.

Product portfolio: The company should offer a diverse range of products catering to different segments (e.g., generics, OTC, wellness products).

Brand reputation: A well-established brand with a strong market presence will help you attract customers more easily.

Support and training: Does the company provide marketing materials, training, and assistance with managing inventory and distribution? This is crucial for smooth operations.

Pricing and margins: Evaluate the profit margins the company offers and determine if they are competitive in the local market.

To evaluate the best PCD company in India:

Request samples: Test the product quality yourself before committing.

Ask for references: Speak with other franchisees of the company to get a sense of their experience.

Visit the company: If possible, visit the manufacturer to better understand their operations and customer support.

Step 5: Identify Legal and Regulatory Requirements

In the pharmaceutical industry, compliance with regulations is non-negotiable. Before starting your PCD franchise, ensure that you’re aware of the necessary legal requirements.

Drug license: Obtain a license from the local drug authority to legally distribute pharmaceutical products.

GST registration: As a business owner, you’ll need to register for GST if your turnover exceeds the threshold limit.

Other permits: Depending on your location, there may be additional licenses required for pharmaceutical distribution.

Step 6: Estimate Startup Costs and Profitability

Lastly, determine the financial feasibility of starting a PCD franchise. Calculate your startup costs, including:

Initial franchise fees

Inventory purchases

Office and storage setup

Marketing and advertising expenses

Also, estimate your break-even point and profit margins. Understanding the potential return on investment will give you a clearer picture of your business’s future profitability.

Conclusion

Conducting thorough market research before starting a PCD franchise is essential to making informed decisions that will set your business up for success. By understanding your target market, evaluating demand, analyzing competition, choosing the best PCD company in India, and ensuring compliance with regulations, you’ll be well on your way to launching a profitable PCD franchise.

With the right research and planning, a PCD franchise can be a rewarding and successful venture in the ever-growing pharmaceutical industry. So take the time to gather data, analyze your options, and make informed decisions to ensure the best possible start for your new business.

[news365timesindia]

[ad_1] Quantiphi, a global AI-first digital engineering company and DDReg, a global leader in regulatory expertise today announced a partnership that will address regulatory challenges that pharmaceutical companies, biotechnology firms, medical device and cosmetics manufacturers face by bringing innovations to market more quickly through AI.DDReg Pharma partners with Quantiphi to use power of Artificial Intelligence to datamine Regulatory Intelligence for efficient submissions, faster approvals and enhance complianceNeeti Pant - DDReg Managing Director, said, "DDReg & Quantiphi collaboration harnesses DDReg's unparalleled regulatory knowledge and Quantiphi's innovative technology, along with a deep understanding of artificial intelligence, to revolutionize regulatory processes. Together, we are transforming how the life sciences sector navigates some of its most pressing regulatory challenges, ensuring compliance, enhancing safety, and accelerating the time to market for new therapies. This collaboration will not only address current regulatory demands but also anticipate future needs, providing a solid framework for sustainable growth and innovation. By combining our strengths, we are paving the way for a more streamlined, effective, proactive & cost-efficient approach to regulatory affairs in the life sciences industry."Quantiphi Global Head of Healthcare and Life Sciences, Barinder Marhok said the partnership marries DDReg's expertise in global regulatory process management and securing and renewing government approvals for healthcare interventions with Quantiphi's expertise in AI-managed processes and documents."As the life sciences industry grapples with the ever-evolving regulation landscape, Quantiphi and DDReg have come together to help deliver cutting-edge solutions that streamline regulatory processes across both the drug development and commercialization lifecycle, ultimately helping improve more lives," Marhok said. "Leveraging cloud, data and AI technologies, our joint efforts aim to accelerate approvals, enhance compliance and optimize Life Cycle Management (LCM), ensuring a faster and more efficient path to market."About DDRegDDReg is a global Pharmaceutical Regulatory Services and Pharmacovigilance services provider company with offices in Gurgaon (India), Delaware, California (USA), Cologne (Germany), and Singapore. It is an ISO 9001:2015 & ISO 27001 TV SD certified organization that is involved in a wide variety of regulatory consulting and pharmacovigilance assignments. DDReg services span across global markets and include, European Union, the USA, UK & Australia among developed markets to Asia, Africa, Middle East & GCC, CIS, and LATAM among the emerging markets- driven by WHO.DDReg has supported its clients in ensuring compliance with worldwide regulations for a wide range of products including generics, new drug products, biologics, biosimilars, medical devices & combination products, cosmetics, and consumer products. The team has deep subject matter expertise and a knowledge base of over 120 regulatory bodies for regulatory compliance. DDReg's expansion strategy focuses on leveraging emerging technologies and expanding further into key international markets, especially those that have complex and/or ambiguous regulatory frameworks and growth of the pharmaceutical industry.Follow us on LinkedIn, X, formerly Twitter and Facebook. [ad_2] Source link

[livealthbiopharma]

Livealth Biopharma Pvt Ltd is the leading manufacturer and supplier of generic medical drugs and medicines across India.

[tenchlifesciences]

Tenchlife Sciences is Pharmaceutical based Generic Medical Drugs & Medicine Manufacturer & Supplier in India. We are specialized in Pharmaceutical Capsule Manufacturer, supplier and distributor.

[news365times]

[ad_1] Quantiphi, a global AI-first digital engineering company and DDReg, a global leader in regulatory expertise today announced a partnership that will address regulatory challenges that pharmaceutical companies, biotechnology firms, medical device and cosmetics manufacturers face by bringing innovations to market more quickly through AI.DDReg Pharma partners with Quantiphi to use power of Artificial Intelligence to datamine Regulatory Intelligence for efficient submissions, faster approvals and enhance complianceNeeti Pant - DDReg Managing Director, said, "DDReg & Quantiphi collaboration harnesses DDReg's unparalleled regulatory knowledge and Quantiphi's innovative technology, along with a deep understanding of artificial intelligence, to revolutionize regulatory processes. Together, we are transforming how the life sciences sector navigates some of its most pressing regulatory challenges, ensuring compliance, enhancing safety, and accelerating the time to market for new therapies. This collaboration will not only address current regulatory demands but also anticipate future needs, providing a solid framework for sustainable growth and innovation. By combining our strengths, we are paving the way for a more streamlined, effective, proactive & cost-efficient approach to regulatory affairs in the life sciences industry."Quantiphi Global Head of Healthcare and Life Sciences, Barinder Marhok said the partnership marries DDReg's expertise in global regulatory process management and securing and renewing government approvals for healthcare interventions with Quantiphi's expertise in AI-managed processes and documents."As the life sciences industry grapples with the ever-evolving regulation landscape, Quantiphi and DDReg have come together to help deliver cutting-edge solutions that streamline regulatory processes across both the drug development and commercialization lifecycle, ultimately helping improve more lives," Marhok said. "Leveraging cloud, data and AI technologies, our joint efforts aim to accelerate approvals, enhance compliance and optimize Life Cycle Management (LCM), ensuring a faster and more efficient path to market."About DDRegDDReg is a global Pharmaceutical Regulatory Services and Pharmacovigilance services provider company with offices in Gurgaon (India), Delaware, California (USA), Cologne (Germany), and Singapore. It is an ISO 9001:2015 & ISO 27001 TV SD certified organization that is involved in a wide variety of regulatory consulting and pharmacovigilance assignments. DDReg services span across global markets and include, European Union, the USA, UK & Australia among developed markets to Asia, Africa, Middle East & GCC, CIS, and LATAM among the emerging markets- driven by WHO.DDReg has supported its clients in ensuring compliance with worldwide regulations for a wide range of products including generics, new drug products, biologics, biosimilars, medical devices & combination products, cosmetics, and consumer products. The team has deep subject matter expertise and a knowledge base of over 120 regulatory bodies for regulatory compliance. DDReg's expansion strategy focuses on leveraging emerging technologies and expanding further into key international markets, especially those that have complex and/or ambiguous regulatory frameworks and growth of the pharmaceutical industry.Follow us on LinkedIn, X, formerly Twitter and Facebook. [ad_2] Source link

[sapana22]

Healthcare Contract Manufacturing Research Current as Well as the Future Challenges

Healthcare Contract Manufacturing Market Opportunities, Size, Demand and Sales by 2031

The 2025 Healthcare Contract Manufacturing Market Report provides a comprehensive analysis of the Healthcare Contract Manufacturing Market industry, presenting key findings on market size, growth projections, and major trends. This report includes detailed segmentation by region, product type, end-user, and application, offering targeted insights to guide strategic decision-making. The analysis encompasses industry dynamics, highlighting growth drivers, challenges, and future opportunities. Key stakeholders, including CEOs and analysts, will benefit from both SWOT and PESTLE analyses, which examine competitive strengths, vulnerabilities, opportunities, and threats across various regions and industry segments.

According to Straits Research, the global Healthcare Contract Manufacturing Market size was valued at USD 255.11 Billion in 2022. It is projected to grow from USD XX Billion in 2023 to USD 1201.32 Billion by 2031, with a projected CAGR of 18.8% over the forecast period (2023–2031).

Request a Free Sample (Free Executive Summary at Full Report Starting from USD 1850): https://straitsresearch.com/report/healthcare-contract-manufacturing-market/request-sample

New Features in the 2024 Report:

Expanded Industry Overview: A more detailed examination of the industry landscape.

In-Depth Company Profiles: Enhanced profiles providing extensive information on key market players.

Customized Reports and Analyst Assistance: Tailored reports and direct access to analyst support available upon request.

Healthcare Contract Manufacturing Market Insights: Analysis of the latest developments and upcoming growth opportunities.

Regional and Country-Specific Reports: Personalized reports focused on specific regions and countries to address unique requirements.

Top Players in the Healthcare Contract Manufacturing Market

The report highlights leading companies, including 

Jabil, Inc.

Celestica, Inc.

Integer Holdings Corp.

Plexus Corp.

Sanmina Corp.

West Pharmaceutical Services, Inc.

Flex Ltd.

Viant

Synecco Ltd.

Nordson MEDICAL

Catalent, Inc.

Healthcare Contract Manufacturing Market Segmental Analysis

By Type

Medical Devices

Services

Accessories Manufacturing

Assembly Manufacturing

Component Manufacturing

Devices Manufacturing

Indication

Cardiology

Diagnostic Imaging

Orthopedic

IVD

Ophthalmic

General and Plastic Surgery

Drug Delivery

Dental

Endoscopy

Diabetes Care

Others

Pharmaceuticals

Service

API/bulk drugs

Advanced Drug Delivery Formulations

Packaging

Finished Dose Formulations

Market Segmentation with Insights-Driven Strategy Guide: https://straitsresearch.com/report/healthcare-contract-manufacturing-market/segmentation

Report Structure:

Healthcare Contract Manufacturing Market Overview: Introduction to the Healthcare Contract Manufacturing Market and its key features.

Economic Impact: Analysis of economic effects on the industry.

Production and Opportunities: Examination of production processes and business opportunities.

Trends and Technologies: Overview of emerging trends, new technologies, and key industry players.

Cost and Market Analysis: Insights into manufacturing costs, marketing strategies, regional market shares, and segmentation by type and application.

Regional Analysis:

North America: Leading the Healthcare Contract Manufacturing Market, driven by technological advancements, high consumer adoption rates, and favorable regulatory conditions, primarily in the United States and Canada.

Europe: Experiencing steady growth supported by stringent regulations, a strong focus on sustainability, and increased R&D investments in countries like Germany, France, the UK, and Italy.

Asia-Pacific: The fastest-growing regional market, with significant growth fueled by rapid industrialization, urbanization, and a rising middle class in China, India, Japan, and South Korea.

Latin America, Middle East, and Africa: Emerging growth regions, driven by economic development and improved infrastructure, particularly in Brazil, Mexico, Saudi Arabia, the UAE, and South Africa.

Buy Full Report (Exclusive Insights with In-Depth Data Supplement) :https://straitsresearch.com/buy-now/healthcare-contract-manufacturing-market

Key Unit Economics for C-Suite Consideration

The report details essential unit economics that Healthcare Contract Manufacturing Market manufacturers should track, including:

Cost of Goods Sold (COGS), R&D Costs, SG&A Expenses

Distribution, Warranty, and After-Sales Costs

Revenue per Unit and Gross Margin

Break-even Point and Customer Acquisition Costs (CAC)

Customer Lifetime Value (LTV)

Capital Expenditures (CapEx) and Economies of Scale

Profit Margin

FAQs Addressed in the Healthcare Contract Manufacturing Market Research Report:

What recent brand-building initiatives have key players undertaken to enhance customer value in the Healthcare Contract Manufacturing Market?

Which companies have broadened their focus through long-term societal initiatives?

How have firms successfully navigated the pandemic, and what strategies have they adopted to remain resilient?

What are the global trends in the Healthcare Contract Manufacturing Market, and will demand increase or decrease in the coming years?

Where will strategic developments lead the industry in the mid to long term?

What factors influence the final price of absorption cooling devices, and what raw materials are utilized in their manufacturing?

How significant is the growth opportunity for the Healthcare Contract Manufacturing Market, and how will increasing adoption in mining affect the market's growth rate?

What recent industry trends can be leveraged to create additional revenue streams?

Table of Contents for the Healthcare Contract Manufacturing Market Report: https://straitsresearch.com/report/healthcare-contract-manufacturing-market/toc

Scope of the Report:

Impact of COVID-19: Analyzes both immediate and long-term effects of the pandemic on the industry.

Industry Chain Analysis: Examines disruptions to the industry chain and changes in marketing channels.

Impact of the Middle East Crisis: Assesses the ongoing Middle East crisis's influence on industry stability, supply chains, and market trends.

About Us: Straits Research is a leading research and intelligence organization specializing in analytics, advisory services, and providing business insights through comprehensive research reports.

Contact Us:

Email: sales@straitsresearch.com

Address: 825 3rd Avenue, New York, NY, USA, 10022

Phone: +1 646 905 0080 (U.S.) | +91 8087085354 (India) | +44 203 695 0070 (U.K.)

[rightaidhomeopathy]

Homeopathy, an alternative medical practice focused on using highly diluted substances, continues to gain popularity worldwide for its natural approach to wellness. For those new to homeopathy, finding reliable products that meet both quality and efficacy standards can be a crucial step in experiencing its full benefits. Here’s a guide to help you choose dependable homeopathy products.

1. Choose Recognized Brands

When selecting homeopathic remedies, go for brands known for their quality and reliability. Reputable companies often adhere to rigorous manufacturing standards, ensuring the purity and potency of their products. These brands are typically well-regulated and undergo regular inspections, especially in countries with established homeopathic standards, like the United States and parts of Europe.

2. Check for Proper Certifications

Certifications from regulatory bodies like the Food and Drug Administration (FDA) in the U.S. or other homeopathic councils worldwide can be an indicator of a product’s reliability. Products that have these certifications meet certain quality standards and are likely to be both safe and effective. In India, the Central Council for Research in Homeopathy (CCRH) offers guidance on standardized practices, so products approved by them are often trustworthy.

3. Read Labels and Product Descriptions Carefully

A reliable homeopathic product should list all ingredients, including their potencies, dilution levels, and any additional compounds. Understanding these components helps you ensure you’re getting a product that matches your needs and expectations. Some reliable brands also provide batch information or expiry dates, an important feature that indicates freshness and potency.

4. Research Reviews and Recommendations

Customer reviews and recommendations from qualified homeopathic practitioners can provide insights into a product's effectiveness. Online forums, testimonials, and dedicated homeopathy websites are excellent places to gather feedback from users who have tried specific remedies. Consulting a certified homeopath also offers personalized recommendations tailored to your health profile.

5. Look for Availability and Ease of Use

Reliable homeopathic remedies are often easy to administer and available in various forms, including tablets, liquids, and creams, to suit different preferences. These products are generally accessible through health stores or trusted online retailers specializing in natural wellness, where you can check customer feedback and product information directly.

Conclusion

Finding reliable homeopathic products involves choosing well-known brands, looking for proper certifications, reading labels, and considering user feedback. By following these steps, you can confidently select remedies that align with the high-quality standards necessary for safe and effective homeopathy.

[marketanalysisdata]

Pharmaceutical Packaging Market Analysis Report - Industry Trends, Growth and Segmentation 2030

In 2023, the global pharmaceutical packaging market reached a valuation of USD 139.37 billion and is projected to grow at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2030. This growth is largely driven by the rapid expansion of the pharmaceutical industry, which has seen significant advancements in science and technology in recent years. These advancements are anticipated to continue driving demand, especially in emerging markets like China, India, Saudi Arabia, and Brazil, where pharmaceutical production and healthcare services are expanding rapidly.

The United States holds the largest pharmaceutical market share worldwide. Key factors behind this include the nation’s extensive healthcare infrastructure, high per capita income, and significant investments in drug research and development. The rise in generic drugs and improved access to healthcare services in the U.S. are also expected to create promising opportunities for pharmaceutical packaging over the coming years. Additionally, the 21st Century Cures Act (Cures Act), signed into law on December 13, 2016, was enacted to accelerate the development and approval of medical products, encouraging innovations that are anticipated to drive demand for pharmaceutical packaging in the U.S.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Packaging Market

In Europe, the pharmaceutical industry is a crucial component of the economy and is one of the region's most high-performing and technologically advanced sectors. Recent years have seen a significant shift toward the development of biopharmaceutical drugs, a focus that has grown substantially. Biopharmaceuticals often require specialized packaging, as many biotechnology-derived drug therapies are unstable in liquid form and are instead offered as lyophilized (freeze-dried) or dry powder formulations. These specialized dosage forms demand advanced packaging solutions to maintain the drugs' stability and efficacy, creating new opportunities for packaging manufacturers to innovate.

The pharmaceutical packaging market is diverse and fragmented, featuring large and medium-sized international companies alongside smaller domestic players. Key players in this market include Amcor plc, Becton, Dickinson and Company, AptarGroup, Inc., Drug Plastics Group, Gerresheimer AG, Schott AG, O-I Glass, Inc., SGD Pharma, West Pharmaceutical Services, Inc., Berry Global Group, Inc., WestRock Company, International Paper, Comar, LLC, CCL Industries, and Vetter Pharma International.

Product Segmentation Insights:

Pharmaceutical packaging is categorized into three main types: primary, secondary, and tertiary packaging. In 2023, primary packaging accounted for the largest share of the market. Primary packaging refers to materials such as bottles, tubes, and blister packs that come into direct contact with the drug, protecting it from contamination and aiding in safe storage. Primary packaging often also plays a role in dispensing and dosing, and manufacturers are focusing on user-friendly designs, including easy-open closures and dispensing systems that ensure the correct dose is given at the appropriate time. These advancements are especially beneficial for elderly populations, who may need additional support in handling medication.

Secondary pharmaceutical packaging is the next layer of protection, grouping multiple primary packages to safeguard them from external impacts. This packaging is critical for both branding and logistics. It not only helps protect the drug but also serves as a marketing tool by displaying the product in an attractive way. Secondary packaging also makes it easier to handle and transport multiple units, which is important for distribution efficiency.

Tertiary packaging, on the other hand, is used to wrap or bundle large groups of products, facilitating safe handling and transportation of goods across long distances. Examples of tertiary packaging include brown cardboard boxes, shrink wraps, and plastic bags. The growth of e-pharmacy (online pharmaceutical sales) has contributed to the increased need for tertiary packaging, as it ensures the safe and efficient transport of pharmaceutical products directly to consumers. This trend is expected to further drive demand for tertiary packaging over the forecast period.

Order a free sample PDF of the Pharmaceutical Packaging Market Intelligence Study, published by Grand View Research.